Filing Flows › Comparisons › AMRX vs UTHR
Amneal Pharmaceuticals vs United Therapeutics: AMRX and UTHR compared
Amneal Pharmaceuticals is the larger company: $863M of revenue in its latest quarter (Q3 2026) against $832M for United Therapeutics (Q3 2026). Amneal Pharmaceuticals is growing faster (+10% against +4% a year earlier). United Therapeutics is more profitable, with an operating margin of 37.0% against 11.1%.
Where the money goes: AMRX and UTHR
Amneal Pharmaceuticals (AMRX) · Q3 2026
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
United Therapeutics (UTHR) · Q3 2026
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
| Amneal Pharmaceuticals (AMRX) | United Therapeutics (UTHR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $863M | $832M |
| Revenue growth, Y/Y | +10% | +4% |
| Gross margin | 38.7% | 88.1% |
| Operating margin | 11.1% | 37.0% |
| Net earnings | $12.3M | $259M |
| Net margin | 1.4% | 31.1% |
| Operating cash flow | $98.3M | $306M |
| Free cash flow | $66.5M | $126M |
| Market value | $6.6B | $25.5B |
| P/E | 30.7× | 21.2× |
| Analysts’ mean target | $23.86 | $670.93 |
Where the revenue comes from
United Therapeutics
- Total Tyvaso: $504M (61%)
- Orenitram: $145M (17%)
- Remodulin: $122M (15%)
- Unituxin: $52.3M (6%)
Questions
Which is bigger, Amneal Pharmaceuticals or United Therapeutics?
Amneal Pharmaceuticals is the larger company: $863M of revenue in its latest quarter (Q3 2026) against $832M for United Therapeutics (Q3 2026).
Is Amneal Pharmaceuticals or United Therapeutics growing faster?
Amneal Pharmaceuticals is growing faster (+10% against +4% a year earlier).
Which is more profitable, Amneal Pharmaceuticals or United Therapeutics?
United Therapeutics is more profitable, with an operating margin of 37.0% against 11.1%.
More: Amneal Pharmaceuticals earnings · how Amneal Pharmaceuticals makes money · United Therapeutics earnings · how United Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (8-K filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.